StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report report published on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Up 2.9 %

NASDAQ:TTNP opened at $7.21 on Tuesday. Titan Pharmaceuticals has a 12 month low of $5.00 and a 12 month high of $16.60. The company has a market cap of $6.59 million, a PE ratio of -0.88 and a beta of 1.33. The company has a 50 day simple moving average of $7.34 and a two-hundred day simple moving average of $7.17.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.